83 related articles for article (PubMed ID: 15740555)
1. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis.
Liao YW; Hung WT; Chen YM; Hsu CY; Lin CH; Hsieh TY; Chen HH; Hsieh CW; Lin CT; Lai KL; Tang KT; Tseng CW; Chen YH; Huang WN
J Clin Rheumatol; 2022 Mar; 28(2):e633-e637. PubMed ID: 34371515
[TBL] [Abstract][Full Text] [Related]
3. Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
Gardiner KM; Tett SE; Staatz CE
Drugs R D; 2018 Dec; 18(4):271-282. PubMed ID: 30426342
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients.
Labriffe M; Micallef L; Woillard JB; Monchaud C; Saint-Marcoux F; Debord J; Marquet P
Ther Drug Monit; 2023 Oct; 45(5):591-598. PubMed ID: 36823705
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.
Suzuki Y; Ishiguro S; Shimada H; Ohgami M; Suzuki M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):633-638. PubMed ID: 38148336
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated Mycophenolate Sodium therApy versus cyclophosphamide for induction of Remission in Microscopic PolyAngiitis (EMSAR-MPA trial): study protocol for a randomised controlled trial.
Li S; Yao S; Tie X; Shi X; Feng R; Su X; Wang L
BMJ Open; 2024 Mar; 14(3):e074662. PubMed ID: 38471694
[TBL] [Abstract][Full Text] [Related]
7. The use of mycophenolate mofetil area under the curve.
Chakrabarti K; Frame D; Al Abbas M; McCune WJ
Curr Opin Rheumatol; 2021 May; 33(3):221-232. PubMed ID: 33741807
[TBL] [Abstract][Full Text] [Related]
8. Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial.
Alex G; Shanoj KC; Varghese DR; Sageer Babu AS; Reji R; Shenoy PD
Semin Arthritis Rheum; 2023 Dec; 63():152270. PubMed ID: 37820508
[TBL] [Abstract][Full Text] [Related]
9. Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate.
Simpson JB; Sekela JJ; Graboski AL; Borlandelli VB; Bivins MM; Barker NK; Sorgen AA; Mordant AL; Johnson RL; Bhatt AP; Fodor AA; Herring LE; Overkleeft H; Lee JR; Redinbo MR
Gut Microbes; 2022; 14(1):2107289. PubMed ID: 35953888
[TBL] [Abstract][Full Text] [Related]
10. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study.
Manger B; Hiepe F; Schneider M; Worm M; Wimmer P; Paulus EM; Schwarting A
Clin Exp Gastroenterol; 2015; 8():205-13. PubMed ID: 26229499
[TBL] [Abstract][Full Text] [Related]
11. Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements.
Khan MH; Onyeaghala GC; Rashidi A; Holtan SG; Khoruts A; Israni A; Jacobson PA; Staley C
Gut Microbes; 2022; 14(1):2108279. PubMed ID: 35921529
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Mycophenolate Mofetil Permeation for Topical Use by Eucalyptol and N-Methyl-2-pyrrolidone.
Amnuaikit T; Songkram C; Pinsuwan S
Scientifica (Cairo); 2016; 2016():9672718. PubMed ID: 27069715
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of a mycophenolic acid metabolite in patients with kidney failure negatively affect cardiomyocyte health.
Harlacher E; Schulte C; Vondenhoff S; Schmitt-Kopplin P; Diederich P; Hemmers C; Moellmann J; Wollenhaupt J; Veltrop R; Biessen E; Lehrke M; Peters B; Schlieper G; Kuppe C; Floege J; Jankowski V; Marx N; Jankowski J; Noels H
Front Cardiovasc Med; 2024; 11():1346475. PubMed ID: 38510194
[TBL] [Abstract][Full Text] [Related]
14. Physical and Chemical Stability of Mycophenolate Mofetil (MMF) Suspension Prepared at the Hospital.
Fahimi F; Baniasadi S; Mortazavi SA; Dehghan H; Zarghi A
Iran J Pharm Res; 2012; 11(1):171-5. PubMed ID: 24250439
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid inhibits replication of Type 2 Winnipeg, a cerebrospinal fluid-derived reovirus isolate.
Hermann LL; Coombs KM
Can J Infect Dis Med Microbiol; 2004 Sep; 15(5):261-5. PubMed ID: 18159503
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.
Johnston A; He X; Holt DW
Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710
[TBL] [Abstract][Full Text] [Related]
17. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?
Lang DM
Curr Allergy Asthma Rep; 2008 Mar; 8(1):37-44. PubMed ID: 18377773
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine: clinical pharmacokinetics and drug interactions.
Knadler MP; Lobo E; Chappell J; Bergstrom R
Clin Pharmacokinet; 2011 May; 50(5):281-94. PubMed ID: 21366359
[TBL] [Abstract][Full Text] [Related]
19. Enteric-coated mycophenolate sodium.
Budde K; Dürr M; Liefeldt L; Neumayer HH; Glander P
Expert Opin Drug Saf; 2010 Nov; 9(6):981-94. PubMed ID: 20795786
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.
Li X; Li S; Fan W; Rokohl AC; Ju S; Ju X; Guo Y; Heindl LM
Int Ophthalmol; 2023 Apr; 43(4):1437-1449. PubMed ID: 36272013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
